The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
Phase 2 study of pembrolizumab as first-line therapy for PD-L1–positive metastatic triple-negative breast cancer (mTNBC): Preliminary data from KEYNOTE-086 cohort B.
 
Sylvia Adams
No Relationships to Disclose
 
Sherene Loi
Research Funding - Bristol-Myers Squibb (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - PI3K pathway gene signature granted by the European and US patent offices (Inst)
 
Deborah Toppmeyer
Employment - Novartis (I)
Leadership - Novartis (I)
Stock and Other Ownership Interests - Novartis (I)
 
David W. Cescon
Consulting or Advisory Role - Genomic Health
Research Funding - GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Michele De Laurentiis
Consulting or Advisory Role - AstraZeneca; Novartis; Pfizer; Roche
 
Rita Nanda
Honoraria - Genentech/Roche
Consulting or Advisory Role - Genentech/Roche; Novartis; Peregrine Pharmaceuticals; Pfizer; Puma Biotechnology
Research Funding - Celgene; Corcept Therapeutics; Merck
 
Eric P. Winer
Consulting or Advisory Role - Genentech/Roche; Leap Therapeutics; Novartis; Verastem
Research Funding - Genentech/Roche (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Genentech/Roche
 
Hirofumi Mukai
Honoraria - AstraZeneca; Eisai; Novartis; Pfizer; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Nippon Kayaku (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst)
 
Kenji Tamura
No Relationships to Disclose
 
Anne Armstrong
Consulting or Advisory Role - Roche; Syndax
 
Minetta C. Liu
Research Funding - Celgene (Inst); Eisai (Inst); GRAIL (Inst); Merck (Inst); Novartis (Inst); Roche/Genentech (Inst); Seattle Genetics (Inst); Veridex (Inst)
Travel, Accommodations, Expenses - Celgene; GRAIL; Merck
 
Hiroji Iwata
No Relationships to Disclose
 
Larisa Ryvo
No Relationships to Disclose
 
Pauline Wimberger
Honoraria - Novartis; Roche
 
Deborah Card
Employment - Merck
Stock and Other Ownership Interests - Merck
Research Funding - Merck
 
Yu Ding
Employment - Bristol-Myers Squibb; Merck; Trevena (I)
Stock and Other Ownership Interests - Merck; Trevena (I)
 
Vassiliki Karantza
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Peter Schmid
Honoraria - AstraZeneca
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; Celgene; Eisai; Genentech/Roche (I); Merck; Novartis; Pfizer; Puma Biotechnology
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Genentech (Inst); Medivation (Inst); Novartis (Inst); Oncogenex (Inst)